PMID- 29456509
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 9
DP  - 2018
TI  - Curcumin Inhibits Growth of Human NCI-H292 Lung Squamous Cell Carcinoma Cells by 
      Increasing FOXA2 Expression.
PG  - 60
LID - 10.3389/fphar.2018.00060 [doi]
LID - 60
AB  - Lung squamous cell carcinoma (LSCC) is a common histological lung cancer subtype, 
      but unlike lung adenocarcinoma, limited therapeutic options are available for 
      treatment. Curcumin, a natural compound, may have anticancer effects in various 
      cancer cells, but how it may be used to treat LSCC has not been well studied. 
      Here, we applied curcumin to a human NCI-H292 LSCC cell line to test anticancer 
      effects and explored underlying potential mechanisms of action. Curcumin 
      treatment inhibited NCI-H292 cell growth and increased FOXA2 expression in a 
      time-dependent manner. FOXA2 expression was decreased in LSCC tissues compared 
      with adjacent normal tissues and knockdown of FOXA2 increased NCI-H292 cells 
      proliferation. Inhibition of cell proliferation by curcumin was attenuated by 
      FOXA2 knockdown. Moreover inhibition of STAT3 pathways by curcumin increased 
      FOXA2 expression in NCI-H292 cells whereas a STAT3 activator (IL-6) significantly 
      inhibited curcumin-induced FOXA2 expression. Also, SOCS1 and SOCS3, negative 
      regulators of STAT3 activity, were upregulated by curcumin treatment. Thus, 
      curcumin inhibited human NCI-H292 cells growth by increasing FOXA2 expression via 
      regulation of STAT3 signaling pathways.
FAU - Tang, Lingling
AU  - Tang L
AD  - Department of Respiratory Medicine, Putuo Hospital, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Liu, Jinjin
AU  - Liu J
AD  - Department of Respiratory Medicine, Putuo Hospital, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Zhu, Linyun
AU  - Zhu L
AD  - Department of Respiratory Medicine, Putuo Hospital, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Chen, Qingge
AU  - Chen Q
AD  - Department of Respiratory Medicine, Putuo Hospital, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Meng, Ziyu
AU  - Meng Z
AD  - Department of Respiratory Medicine, Putuo Hospital, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Sun, Li
AU  - Sun L
AD  - Department of Respiratory Medicine, Putuo Hospital, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Hu, Junsheng
AU  - Hu J
AD  - Department of Respiratory Medicine, Putuo Hospital, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Ni, Zhenhua
AU  - Ni Z
AD  - Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Wang, Xiongbiao
AU  - Wang X
AD  - Department of Respiratory Medicine, Putuo Hospital, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20180202
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC5801542
OTO - NOTNLM
OT  - FOXA2
OT  - STAT3
OT  - curcumin
OT  - lung squamous cell carcinoma
OT  - proliferation
EDAT- 2018/02/20 06:00
MHDA- 2018/02/20 06:01
PMCR- 2018/02/02
CRDT- 2018/02/20 06:00
PHST- 2017/09/20 00:00 [received]
PHST- 2018/01/17 00:00 [accepted]
PHST- 2018/02/20 06:00 [entrez]
PHST- 2018/02/20 06:00 [pubmed]
PHST- 2018/02/20 06:01 [medline]
PHST- 2018/02/02 00:00 [pmc-release]
AID - 10.3389/fphar.2018.00060 [doi]
PST - epublish
SO  - Front Pharmacol. 2018 Feb 2;9:60. doi: 10.3389/fphar.2018.00060. eCollection 
      2018.